Eli Lilly's Pirtobrutinib Shows Promising Results in CLL Trials
Pirtobrutinib's Efficacy in Chronic Lymphocytic Leukemia Studies Eli Lilly and Company (NYSE: LLY) made notable advancements in chronic lymphocytic leukemia (CLL) research with their drug, pirtobrutinib. The recent study, known as BRUIN CLL-321, demonstrated that pirtobrutinib significantly reduced the risk of disease progression or death by 46% compared to previous...
Continue Reading